Some tips to help get started:
There are 420 active trials for advanced/metastatic non-small cell lung cancer. Click on a trial to see more information.
420 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls adults with advanced solid tumors harboring RET gene abnormalities, including both NSCLC and other solid tumors, regardless of prior RET inhibitor exposure. Patients receive TAS0953/HM06 (vepafestinib), an oral selective RET tyrosine kinase inhibitor active against resistance mutations and designed for enhanced CNS penetration.
ClinicalTrials.gov ID: NCT04683250
HealthScout AI summary: Eligible patients are adults with advanced NSCLC, head and neck squamous cell carcinoma, cervical cancer, or uterine carcinoma, whose tumors express the NEO-201 antigen and who have progressed after standard therapies. Treatment consists of NEO-201 (a monoclonal antibody targeting tumor-associated O-glycans and CEACAM5/1 pathway) in combination with pembrolizumab.
ClinicalTrials.gov ID: NCT03476681
HealthScout AI summary: Eligible adult patients with advanced or metastatic solid tumors (including melanoma, lung, head and neck, urothelial, gastric, esophageal, cervical, hepatocellular, and other select cancers) who have exhausted or are not candidates for standard therapy may receive DF6002, a novel IL-12 Fc fusion protein designed to enhance anti-tumor immunity, as monotherapy or in combination with nivolumab. Both subcutaneous and intravenous DF6002 dosing routes are under investigation.
ClinicalTrials.gov ID: NCT04423029
HealthScout AI summary: This trial enrolls adults with unresectable or metastatic melanoma or advanced non-small-cell lung cancer who have progressed after at least anti-PD-1/PD-L1 therapy, using an autologous tumor-infiltrating lymphocyte product (IOV-4001) genetically edited to knock out PD-1 via TALEN technology, administered after lymphodepleting chemotherapy and followed by high-dose IL-2. PD-1 knockout aims to enhance TIL antitumor activity by reducing exhaustion.
ClinicalTrials.gov ID: NCT05361174
HealthScout AI summary: Adults with advanced or metastatic solid tumors who have progressed after or are ineligible for standard therapies—including specific expansion cohorts for relapsed/refractory head and neck, non-small cell lung, clear cell renal cell carcinoma, or MSI-H tumors—are eligible to receive ABBV-CLS-484 (an oral PTPN2/PTPN1 inhibitor targeting immune evasion) as monotherapy or combined with a PD-1 inhibitor or VEGFR tyrosine kinase inhibitor.
ClinicalTrials.gov ID: NCT04777994
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors or diffuse large B-cell lymphoma who have exhausted standard therapies, evaluating the investigational oral CBL-B inhibitor NX-1607 (which enhances antitumor immunity by blocking a negative regulator of immune cell activation) as monotherapy or in combination with paclitaxel. Eligible tumor types include ovarian, gastric, head and neck, melanoma, NSCLC, prostate, mesothelioma, triple-negative breast, urothelial, cervical, microsatellite-stable colorectal cancer, and DLBCL/Richter transformation.
ClinicalTrials.gov ID: NCT05107674
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring RAS/MAPK pathway mutations (including KRAS, NF1, or RAF), who have progressed on prior therapy, and tests the selective ULK1/2 inhibitor inlexisertib (DCC-3116), alone or in combination with RAS/MAPK pathway inhibitors such as sotorasib. The dose expansion focuses on patients with KRAS G12C-mutant non-small cell lung cancer who are naïve to KRAS G12C inhibitors.
ClinicalTrials.gov ID: NCT04892017
HealthScout AI summary: This trial enrolls adults with advanced solid tumors or lymphoma that are refractory to standard therapies, whose tumors overexpress TrkA or harbor an NTRK1 gene fusion, to receive oral VMD-928, a highly selective irreversible TrkA inhibitor that acts via allosteric dimerization and inactivation of the target. Key exclusions include significant comorbidities and impaired drug absorption.
ClinicalTrials.gov ID: NCT03556228
HealthScout AI summary: This trial enrolls adults with metastatic EGFR-mutant (exon 19 or 21) non-small cell lung cancer, either treatment-naive or previously treated with EGFR TKIs, to receive osimertinib plus MRX-2843, an investigational oral MERTK/FLT3 tyrosine kinase inhibitor. The study aims to assess safety and optimal dosing for the combination in both TKI-naive and TKI-resistant settings.
ClinicalTrials.gov ID: NCT04762199
HealthScout AI summary: This trial enrolls patients with BRAF V600E/K mutant cancers who previously received and benefited from dabrafenib (a BRAF inhibitor), trametinib (a MEK inhibitor), or their combination in Novartis or GSK-sponsored studies, and who lack access to commercial therapy. Patients continue their prior targeted regimen to assess long-term safety and tolerability.
ClinicalTrials.gov ID: NCT03340506